Pfizer is adding follow-on biologics to pipeline

04/27/2010 | Wall Street Journal, The

Pfizer is working to boost its biotech business by developing new versions of blockbuster treatments, including formulations of blood cancer drug Rituxan and rheumatoid arthritis medicine Enbrel that require fewer injections. The company is using Trubion Pharmaceuticals' technology to tailor the "bio-betters," some of which are in midstage development.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC